A visual journey into AKT inhibition

Indication and Usage

Capivasertib (TRUQAP®) in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Description:

This animation shines a light on AKT inhibition, guiding you through the distinctive mechanism of action of capivasertib, which restricts the flow of oncogenic signaling within the PI3K/AKT/PTEN pathway.1 You will discover how capivasertib’s inhibition of AKT, the ‘master switch’ of the PI3K/AKT/PTEN pathway, inhibits pathway hyperactivation driven by alterations in PIK3CA, AKT1 or PTEN.2–6

Key messages:

• Amplified oncogenic signaling can occur as a result of PIK3CA and AKT1 activating mutations, or PTEN inactivating alterations3,5,6
• Capivasertib inhibits all three isoforms of AKT (AKT1, AKT2, and AKT3), which inhibits the phosphorylation of downstream AKT substrates1
• By inhibiting AKT, the ‘master switch’ of the PI3K/AKT/PTEN pathway,2 capivasertib restricts pathway hyperactivation driven by alterations in PIK3CA, AKT1 or PTEN3–6

Select Safety Information About capivasertib (TRUQAP®) tablets

TRUQAP is contraindicated in patients with severe hypersensitivity to TRUQAP or any of its components.

Serious adverse reactions include hyperglycemia, including diabetic ketoacidosis and fatal outcomes; diarrhea; and cutaneous adverse reactions. Monitor fasting glucose and hemoglobin A1C levels regularly. May cause fetal harm when administered to a pregnant woman. Among the 355 patients who received TRUQAP in CAPItello-291, the most common (≥20%) adverse reactions, including laboratory abnormalities, were diarrhea (72%), cutaneous adverse reactions (58%), increased random glucose (57%), decreased lymphocytes (47%), decreased hemoglobin (45%), increased fasting glucose (37%), nausea and fatigue (35% each), decreased leukocytes (32%), increased triglycerides (27%), decreased neutrophils (23%), increased creatinine (22%), vomiting (21%), and stomatitis (20%).

Please see full Prescribing Information, including Patient Information for TRUQAP.

References:

1. TRUQAP® (capivasertib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.
2. Uhlenbrock N, et al. Chem Sci. 2019;10(12):3573–3585.
3. Skolariki A, et al. Explor Target Antitumor Ther. 2022;3(2):172–199.
4. Andrikopoulou A, et al. Breast. 2022;63:157–167.
5. Martorana F, et al. Front Pharmacol. 2021;12:662232.
6. Turner NC, et al. N Engl J Med. 2023;388:2058–2070.

TRUQAP is a registered trademark of the AstraZeneca group of companies.

©2025 AstraZeneca. All rights reserved.

US-105463 Last Updated 10/25